Skip to content
10-Q

Quarterly Report

VERTEX PHARMACEUTICALS INC / MA VRTX

0000875320-24-000223

← back to feed
Filed
Nov 5, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Oct 31, 2024 257.53M sh
Current Liabilities Q3 2024 · Sep 30, 2024 $3.97B
Current Liabilities Q3 2024 · Dec 31, 2023 $3.55B
Total Liabilities Q3 2024 · Sep 30, 2024 $6.61B
Total Liabilities Q3 2024 · Dec 31, 2023 $5.15B
Current Assets Q3 2024 · Sep 30, 2024 $9.8B
Current Assets Q3 2024 · Dec 31, 2023 $14.14B
Total Assets Q3 2024 · Sep 30, 2024 $22.24B
Total Assets Q3 2024 · Dec 31, 2023 $22.73B
Shares Diluted Q3 2024 · Sep 30, 2023 260.6M sh
Shares Diluted Q3 2024 · Sep 30, 2023 260.4M sh
Stock Repurchased Q3 2024 · Sep 30, 2023 $278.1M
Capex Q3 2024 · Sep 30, 2023 $142.3M
Operating Cash Flow Q3 2024 · Sep 30, 2023 $3.3B
Cash And Equivalents Q3 2024 · Sep 30, 2023 $11.11B
Cash And Equivalents Q3 2024 · Dec 31, 2022 $10.5B
Stockholders Equity Q3 2024 · Sep 30, 2023 $16.51B
Stockholders Equity Q3 2024 · Jun 30, 2023 $15.47B
Stockholders Equity Q3 2024 · Dec 31, 2022 $13.91B
Eps Diluted Q3 2024 · Sep 30, 2023 $3.97
Eps Diluted Q3 2024 · Sep 30, 2023 $10.18
Eps Basic Q3 2024 · Sep 30, 2023 $4.01
Eps Basic Q3 2024 · Sep 30, 2023 $10.29
Sga Expense Q3 2024 · Sep 30, 2023 $263.8M
Sga Expense Q3 2024 · Sep 30, 2023 $767.5M
Net Income Q3 2024 · Sep 30, 2023 $1.04B
Net Income Q3 2024 · Sep 30, 2023 $2.65B
Operating Income Q3 2024 · Sep 30, 2023 $1.04B
Operating Income Q3 2024 · Sep 30, 2023 $2.84B
Cost Of Revenue Q3 2024 · Sep 30, 2023 $318.7M
Cost Of Revenue Q3 2024 · Sep 30, 2023 $894.2M
Revenue Q3 2024 · Sep 30, 2023 $2.48B
Revenue Q3 2024 · Sep 30, 2023 $7.35B